K-STREET TRACKER

FOLLOW THE MONEY INTO THE SWAMP

Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.

Filings tracked

19,882

thru 2026-05-08

Total reported $

$2.7B

disclosed lobbying

Distinct clients

2,220

paying companies

Tickers targeted

1,207

public companies

💸 Top Spending Clients

#	Client	Filings	Total $
1	PFIZER INC.PFE	47	$46.8M
2	GENERAL MOTORS COMPANY GM	61	$46.8M
3	META PLATFORMS INC. AND VARIOUS SUBSIDIARIES META	12	$44.9M
4	VISA INC.V	45	$37.7M
5	AMAZON.COM SERVICES LLC AMZN	36	$32.8M
6	LOCKHEED MARTIN CORPORATION LMT	73	$29.0M
7	FEDEX CORPORATION FDX	69	$27.8M
8	ELI LILLY AND COMPANY LLY	56	$27.1M
9	ALTRIA CLIENT SERVICES LLC MO	142	$25.2M
10	AMGEN INC AMGN	19	$24.9M
11	COMCAST CORPORATION CMCSV	179	$24.7M
12	MERCK & CO INC MRK	14	$24.0M
13	SOUTHERN COMPANY SO	53	$23.9M
14	GOOGLE CLIENT SERVICES LLC GOOGL	79	$22.6M
15	APPLE INC AAPL	9	$22.1M
16	T-MOBILE USA INC.TMUS	121	$21.0M
17	UNITEDHEALTH GROUP INC UNH	19	$20.4M
18	VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIES VZ	40	$20.1M
19	OCCIDENTAL PETROLEUM CORPORATION OXY	30	$19.7M
20	MICROSOFT CORPORATION MSFT	103	$18.8M
21	QUALCOMM INCORPORATED QCOM	40	$17.2M
22	GENERAL DYNAMICS CORP GD	11	$17.0M
23	BOEING COMPANY BA	23	$16.9M
24	THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI	13	$16.9M
25	ORACLE CORPORATION ORCL	58	$16.7M

🎯 Top Lobbied Tickers

#	Ticker	Filings	Total $
1	META Meta Platforms Inc.	129	$50.2M
2	PFE Pfizer Inc.	87	$48.6M
3	GM General Motors Company	103	$48.4M
4	V Visa Inc.	46	$37.7M
5	AMZN Amazon.com Inc.	80	$35.3M
6	LMT Lockheed Martin Corporation	88	$29.4M
7	FDX FedEx Corporation	82	$28.3M
8	LLY Eli Lilly and Company	83	$28.1M
9	AMGN Amgen Inc.	95	$28.0M
10	MRK Merck & Co. Inc.	92	$27.5M
11	AAPL Apple Inc.	64	$26.8M
12	GOOGL Alphabet Inc. Class A	123	$26.6M
13	MO	164	$26.2M
14	SO Southern Company	108	$26.1M
15	UNH UnitedHealth Group Inc.	67	$23.9M
16	VZ Verizon Communications Inc.	116	$23.8M
17	TMUS	159	$22.7M
18	CHTR	137	$22.6M
19	GD General Dynamics Corporation	127	$22.5M
20	T AT&T Inc.	134	$21.6M
21	ORCL Oracle Corporation	132	$20.6M
22	CMCSA Comcast Corporation	141	$20.4M
23	CI The Cigna Group	64	$19.9M
24	OXY Occidental Petroleum Corporation	36	$19.9M
25	MSFT Microsoft Corporation	122	$19.2M

🆕 Filtered Filings · COHERUS BIOSCIENCES INC.

clear filters

Date	Ticker	Client	Registrant	Amount	Issue
2026-03-09	CHRS	COHERUS BIOSCIENCES INC.	COHERUS BIOSCIENCES, INC.	$80K	Issues related to oncology, Medicare coverage, domestic production of essential drugs, supply chain security, PILLS Act, Biosecure Act, Loans and grants for biologic production Issues related to drug development, oncology, IRA implementation, supply chain security, BIOSECURE as a policy matter, PILLS Act, and domestic production of essential drugs. Strategic National Stockpile of acute radiation syndrome medical counter measures. Administration for Strategic Preparedness & Response.
2025-10-22	CHRS	COHERUS BIOSCIENCES INC.	COHERUS BIOSCIENCES, INC.	$80K	Issues related to oncology, Medicare coverage, domestic production of essential drugs, supply chain security, PILLS Act, Biosecure Act, Loans and grants for biologic production Issues related to drug development, oncology, IRA implementation, supply chain security, BIOSECURE as a policy matter, PILLS Act, and domestic production of essential drugs. Strategic National Stockpile of acute radiation syndrome medical counter measures. Administration for Strategic Preparedness & Response.
2025-08-18	CHRS	COHERUS BIOSCIENCES INC.	COHERUS BIOSCIENCES, INC.	$125K	Issues related to oncology, Medicare coverage, domestic production of essential drugs, supply chain security, PILLS Act, Biosecure Act, Loans and grants for biologic production Issues related to drug development, oncology, IRA implementation, supply chain security, BIOSECURE as a policy matter, PILLS Act, and domestic production of essential drugs. Strategic National Stockpile of acute radiation syndrome medical counter measures. Administration for Strategic Preparedness & Response.
2025-03-24	CHRS	COHERUS BIOSCIENCES INC.	COHERUS BIOSCIENCES, INC.	$65K	Domestic Manufacturing Medicare implications on biosimilars, Part D reform Drug Rebate Reform Appropriations pertaining to American Made preference HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain 117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S.3311 - American Made Pharmaceuticals Act of 2023 FDA foreign inspections ASPR/BARDA funding and policy Interchangeability of biosimilars legislation Implementation of Buy American and Supply Chain Executive Orders American-Made Policies American-Made Supply Chain Security of the American Pharmaceutical and Medical Supply Chain Biosimilars Policy BARDA funding ASPR funding ARPA-H funding and implementation Industrial Supply and Financing IRA implementation Part D biosimilars utilization
2025-03-24	CHRS	COHERUS BIOSCIENCES INC.	COHERUS BIOSCIENCES, INC.	$65K	Issues related to oncology, Medicare coverage, domestic production of essential drugs, supply chain security, PILLS Act Issues related to drug development, oncology, IRA implementation, supply chain security, BIOSECURE as a policy matter, PILLS Act, and domestic production of essential drugs. Strategic National Stockpile of acute radiation syndrome medical counter measures. Administration for Strategic Preparedness & Response.